Cyxone (publ) announced that national phase filings have been completed in a large number of relevant markets for four of its pending PCT applications directed to clinically applicable forms and formulations of Rabeximod, as well as their medical use, potentially conferring patent protection until 2041. In November 2020 Cyxone reported the filing of five new patent applications though the international patent cooperation treaty (PCT) in order to strengthen the intellectual property protection for Rabeximod. Cyxone reported the continued advancement of the five PCT applications according to plan, where 4 applications now have successfully converted to national phase.

The patents of relevance are: PCT/EP2021/065705: ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD; PCT/EP2021/065697: RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS; PCT/EP2021/065693: NEW USE OF RABEXIMOD; PCT/EP2021/065694: METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD.